These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 2121387

  • 21. Influence of induction therapy on rejection and survival in heart transplantation.
    Almenar L, García-Palomar C, Martínez-Dolz L, Chamorro C, Moro J, Zorio E, Arnau MA, Rueda J, Osa A, Cardo ML.
    Transplant Proc; 2005 Nov; 37(9):4024-7. PubMed ID: 16386616
    [Abstract] [Full Text] [Related]

  • 22. Comparative trial of immunoprophylaxis with RATG versus OKT3.
    Griffith BP, Kormos RL, Armitage JM, Dummer JS, Hardesty RL.
    J Heart Transplant; 1990 Nov; 9(3 Pt 2):301-5. PubMed ID: 2113093
    [Abstract] [Full Text] [Related]

  • 23. Triple-drug immunosuppression for heart transplantation in infants and children.
    Brown JW, Turrentine MW, Kesler KA, Mahomed Y, Darragh R, Evans K, Thompson L, Caldwell R.
    J Heart Lung Transplant; 1993 Nov; 12(6 Pt 2):S265-74. PubMed ID: 8312346
    [Abstract] [Full Text] [Related]

  • 24. Induction therapy with cyclosporine without cytolytic agents results in a low incidence of acute rejection without significant renal impairment in heart transplant patients.
    Jazzar A, Fagiuoli S, Sisson S, Zuhdi N, Cooper DK.
    Clin Transplant; 1995 Aug; 9(4):334-9. PubMed ID: 7579743
    [Abstract] [Full Text] [Related]

  • 25. Increased rejection in gender-mismatched grafts: amelioration by triple therapy.
    Keogh AM, Valantine HA, Hunt SA, Schroeder JS, Oyer PE.
    J Heart Lung Transplant; 1991 Aug; 10(1 Pt 1):106-10. PubMed ID: 2007161
    [Abstract] [Full Text] [Related]

  • 26. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts.
    Menkis AH, Powell AM, Novick RJ, McKenzie FN, Kostuk WJ, Pflugfelder PW, Brown JE, Rochon J, Chow LH, Stiller C.
    J Heart Lung Transplant; 1992 Aug; 11(3 Pt 1):569-76. PubMed ID: 1610866
    [Abstract] [Full Text] [Related]

  • 27. The duration of administration of monoclonal antibody OKT3 for induction immunosuppression after heart transplantation.
    Aleksic I, Freimark D, Blanche C, Czer LS, Dalichau H, Valenza M, Takkenberg JJ, Trento A.
    Thorac Cardiovasc Surg; 1997 Aug; 45(4):190-5. PubMed ID: 9323821
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM, Glanemann M, Guckelberger O, Klupp J, Neumann U, Machens C, Lohmann R, Knoop M, Lobeck H, Schlag H, Keck H, Settmacher U, Bechstein WO, Neuhaus PJ.
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [Abstract] [Full Text] [Related]

  • 36. Annual trends and triple therapy--1991-2000.
    Nishikawa K, Terasaki PI.
    Clin Transpl; 2001 Aug; ():247-69. PubMed ID: 12211788
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.